NMRA Q2 2024 Earnings — Neumora Therapeutics, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

NMRANeumora Therapeutics, Inc. Common Stock

$586M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$64M

Net Income

-$59M

EPS (Diluted)

$-0.37

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$56M

Free Cash Flow

-$56M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$404M

Total Liabilities

$23M

Stockholders' Equity

$381M

Cash & Equivalents

$151M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$64M	-$42M	-51.7%
Net Income	-$59M	-$39M	-52.3%